• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Théa’s ophthalmic products not impacted by Akorn recall

Article

Earlier this year, Théa Pharma Inc. completed the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. Those products are not impacted by Akorn’s recall of all of its drugs as it ceases all operations.

Théa announced this week its portfolio of ophthalmic products acquired earleir this year from Akorn are not affected by the recall. (Image courtesy of Adobe Stock/Wesley JvR)

Théa announced this week its portfolio of ophthalmic products acquired earleir this year from Akorn are not affected by the recall. (Image courtesy of Adobe Stock/Wesley JvR)

Akorn Operating Company LLC announced it is recalling all of its drugs within expiry due to its shutdown, and the company has ceased all operations and terminated all employees at all of its sites in the United States.

According to a news release, the Akorn Trustee is initiating a voluntary recall of various human and pet products as a result of the closures and discontinuation of its quality program. Because of this, the company assure that products meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess which render the products adulterated.

Earlier this year, Théa Pharma Inc. completed the acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. Under the deal, Théa acquired seven products including established glaucoma therapies Zioptan, Cosopt, Cosopt PF, Betimol along with Azasite, Akten, and the ocular surface repair agent AcellFX. 

In a statement Friday, Théa announced its portfolio of products acquired from Akorn are not affected by the recall.

“On April 26, 2023, the Akorn Trustee announced that initiated a voluntary recall of various within-expiry human and animal products as a result of its U.S. facility closures and discontinuation of the Quality activities of these marketed products,” Théa said in a statement. “These products are not impacted by Akorn’s recall. None of these products are manufactured at Akorn’s U.S. facilities that have been closed.”

Théa’s acquisition of the Akorn ophthalmic products was completed in March.

Akorn Operating Company declared Chapter 7 bankruptcy on Feb. 23. Once the company terminated all of its employees, that meant there was no quality control in place.

Akorn hasn’t received any reports of adverse events related to this recall, which is

The products were distributed nationwide to wholesalers, retailers, manufacturers, medical facilities, repackagers, and via the internet to consumers.

Akorn suggested all products be discarded. Consumers with questions regarding this recall can contact Akorn at 800-932-5676.

Related Videos
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
© 2024 MJH Life Sciences

All rights reserved.